Leveraging a four-quadrant approach for evaluating Redpine Science
Organizations: Redpine, Sweden.
Abstract
Redpine Science gives models and agents a single access point to a wide range of peer-reviewed literature, queried directly through the Model Context Protocol (MCP) and an API. This report evaluates Redpine Science on two levels: the relevance of the retrieved chunks, and a model's answer when it has access to Redpine Science compared to web search. Both public and expert-validated benchmarks are used. Public benchmarks are a widely accepted way to test model development and are comparable across labs, but risk saturation and memorization. To address this, we complement them with an expert-validated question set. In total, this report presents four evaluations. On ScholarQABench SciFact, the public answer-quality benchmark reported here, an agent with Redpine Science answers 94.4% of claims correctly against 87.6% with no retrieval. On the expert-validated question set, an agent with Redpine Science states 80.1% of the required claims against 70.2% for an agent restricted to web search. On the 668 queries of a public retrieval benchmark whose gold paper Redpine holds, stripped of any model reasoning, Redpine Science places the correct source paper in its top ten results for 83.1% of queries (Recall@10), against 79.3% for the benchmark's creator. A blinded expert relevance panel places Redpine Science's Precision@5 at 75.2% against 39.8% for the PubMed search tool. We release the expert-validated question set and instructions to reproduce every headline result above, at https://github.com/redpine-ai/benchmarks.
Figures & tables
| Questions | n | Sonnet 5 | Jev |
|---|---|---|---|
| All questions | 179 | ||
| Open access | 105 | ||
| Paywalled | 74 |
| Sonnet 5 | Jev | |
| Agreement with the expert majority, 144 claim units | 90% | 85% |
| Alt-test winning rate, | 100% | 100% |
| Mean Cohen’s against each expert (expert against expert: 0.48) | 0.59 | 0.55 |
| ICC(2,1) against the leave-one-out consensus | 0.86 [0.77, 0.92] | 0.82 [0.71, 0.90] |
| Panel, 154 core claim units | ||
| Experts’ ICC ceiling | 0.74 [0.56, 0.85] | |
| Recall@1 | Recall@5 | Recall@10 | nDCG@10 | |
|---|---|---|---|---|
| Redpine Science | 69.8% | 80.5% | 83.1% | 0.765 |
| Exa | 62.9% | 76.3% | 79.3% | 0.714 |
| Tavily | 48.2% | 57.5% | 60.9% | 0.545 |
Appendix figures & tables2 assets
Supplementary material from the paper’s appendix.
Appendix
| Domain | Subspecialty | Question |
|---|---|---|
| Neurology | Motor neuron disease | Does prior military service increase the risk of developing ALS? |
| Cardiology | Cardiac imaging | In patients with STEMI undergoing primary PCI, is CMR-measured infarct size reliable for predicting 1-year heart failure hospitalization and mortality? |
| Rheumatology | RA immunology and pathogenesis | How does methotrexate treatment affect peripheral blood B cells, such as the B cell repertoire and the frequency of B cell phenotype subtypes? |
| Track | Question | Required claims and scope |
|---|---|---|
| Cardiology | How does in-hospital mortality compare between transcatheter and surgical aortic valve replacement in patients with aortic stenosis? | In-hospital mortality was lower after transcatheter than after surgical aortic valve replacement overall; among patients younger than 75 years, in-hospital mortality did not differ between the transcatheter and surgical approaches. Scope: applies to severe non-rheumatic aortic stenosis treated with aortic valve replacement in adults, predominantly elderly, inpatient settings. |
| Neuroimmunology | Which imaging measures relate to disability progression that occurs independently of relapses in multiple sclerosis? | Measures of cortical damage are central to predicting progression of disability that occurs without relapses; spinal cord degeneration also carries prognostic relevance for disability progression in multiple sclerosis; cortical thickness in the temporal lobe emerged as the strongest imaging predictor of time to relapse-independent progression. Scope: applies to multiple sclerosis in adults under regular clinical evaluation, outpatient settings. |
| Sepsis | How does the timing of norepinephrine initiation after hypotension onset relate to mortality in sepsis? | A longer delay between hypotension onset and the start of norepinephrine is associated with higher 28-day mortality; the delay remains associated with 28-day death after multivariable adjustment for measured covariates; delays extending beyond the first hour after hypotension onset are associated with a higher adjusted hazard of death by day 28. Scope: applies to sepsis with hypotension requiring vasopressor support in adults, mixed settings. |
| Immunology | How do ibrutinib, acalabrutinib, and zanubrutinib compare for atrial fibrillation risk in mantle cell lymphoma? | Newly recorded atrial fibrillation or flutter is less frequent with acalabrutinib than with ibrutinib, on the order of a third as frequent; newly recorded atrial fibrillation or flutter is likewise less frequent with zanubrutinib than with ibrutinib; atrial fibrillation or flutter frequency is similar between acalabrutinib and zanubrutinib, with no clear separation between the two second-generation agents. Scope: applies to mantle cell lymphoma treated with a covalent Bruton tyrosine kinase inhibitor in adults, outpatient settings. |